pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Exondys 51
drug
save

eteplirsen

Marketedupdated 6mo ago
by $SRPT Sarepta Therapeutics, Inc.
Approved
community read0 votes

indications

investigational
Duchenne Muscular Dystrophy

all catalysts(0)

nothing on the calendar yet

Trials studying eteplirsen

  • phase3A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)active not recruitingn=160
  • —A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practiceenrolling by invitationn=300
  • phase2Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatmentterminatedn=62
  • phase2A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.completedn=3
  • phase2A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)terminatedn=15

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 27, 2028
~1.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

  • Mar 14, 2034method-of-use (U-1918)US 10337003
  • Mar 14, 2034method-of-use (U-1918)US 10337003
  • Mar 14, 2034method-of-use (U-1918)US 10364431
  • Mar 14, 2034method-of-use (U-1918)US 10364431
  • Mar 14, 2034method-of-use (U-1919)US 9506058
  • Mar 14, 2034method-of-use (U-1919)US 9506058
  • Feb 2, 2029formulationUS RE477692.2y
  • Feb 2, 2029formulationUS RE477692.2y
  • Oct 27, 2028method-of-use (U-2097)US RE484681.9y
  • Oct 27, 2028method-of-use (U-2097)US RE484681.9y

News(3)

  • Sarepta’s new CEO confident in clinical execution as DMD competitors close in
    Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.
    biospace · 11d ago
  • On the move: 4 rare disease companies hiring now
    Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.
    biospace · 1mo ago
  • Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
    If approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…
    biospace · 3mo ago
brand
Exondys 51
generic
eteplirsen
indication
Duchenne Muscular Dystrophy
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?